The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Relapse-free survival
recurrence and survival will be collected for 5 years after surgery
No
Hiroki Koyama, MD
Principal Investigator
Osaka Medical Center for Cancer and Cardiovascular Diseases
Japan: Ministry of Health, Labor and Welfare
91023033
NCT00152178
July 1996
August 2008
Name | Location |
---|